I was mainly referring to oncology subject. But if you want to look at CLI, 31 phase 3 trials listed. With what results, I don't know. But a lot of competition nonetheless.
With regards to manufacturing, I have shown how others do it now. Only advantage we will have is we cut out having to outsource manufacturing. But others are manufacturing themselves, utilizing technologies from others.
Manufacturing for Pluristem will remain useless, until they get a product to market. Well not entirely, as they don't have a significant manufacturing cost for their own trials. ARS really is their only near to mid term hope. Without something from ARS, they will need significantly more funds. $50 million according to Edison report, by 2020.
If you want to respond, try to counter THIS argument about THIS post, and not come up with something totally different, as you have a tendency to do.
News 
Market Data 
Discover 
